3/7
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/26
11:36 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $21.00 to $22.00. They now have an "overweight" rating on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $21.00 to $22.00. They now have an "overweight" rating on the stock.
2/26
11:36 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/25
04:15 pm
oric
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Medium
Report
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
2/21
01:36 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
2/18
04:05 pm
oric
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Low
Report
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
2/17
01:06 pm
oric
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Medium
Report
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
2/11
08:09 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
High
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
2/10
09:12 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/7
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/6
01:31 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
1/27
04:15 pm
oric
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
1/14
10:57 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/13
06:17 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
1/13
11:12 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/13
08:05 am
oric
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
Medium
Report
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
1/13
08:00 am
oric
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Low
Report
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
1/6
04:15 pm
oric
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
High
Report
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
1/3
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)